OmanDocSign in

Curriculum · Public Health and Communicable Diseases

Recombinant versus live zoster vaccine

What it is

Shingles is an acute, unilateral, painful blistering rash caused by reactivation of the Varicella Zoster Virus (VZV), and two vaccines are set against it: the live zoster vaccine (Zostavax) and the recombinant zoster vaccine (Shingrix).

The live vaccine

In 2013 the NHS introduced a vaccine to boost the immunity of elderly people against herpes zoster. It is offered to all patients aged 70-79 years, and it is live-attenuated and given subcutaneously, as one dose.

Because it is live-attenuated the main contraindication is immunosuppression. In the maternal vaccine table the zoster vaccine is listed as live and contraindicated during pregnancy, in the same row as varicella.

Its side-effects are injection site reactions, and less than 1 in 10,000 individuals will develop chickenpox.

The recombinant vaccine, and why it is preferred

The recombinant zoster vaccine is preferred over the live zoster vaccine due to its increased efficacy.

What is not an advantage

Asked what the advantage of the recombinant vaccine is, improved efficacy is the answer, and the other four offered are each wrong for a stated reason: it is not lower cost, since it is slightly more expensive; it is not subcutaneous administration, since it is intramuscular; it is not proven safety for immunocompromised patients, since the studies are still ongoing; and it is not administration as a single dose, since it needs two.